Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Candriam S.C.A.

Candriam S.C.A. reduced its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 40.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 634,626 shares of the company’s stock after selling 427,333 shares during the quarter. Candriam S.C.A.’s holdings in Nurix Therapeutics were worth $11,956,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new position in Nurix Therapeutics in the fourth quarter valued at $1,026,000. Proficio Capital Partners LLC purchased a new stake in Nurix Therapeutics during the fourth quarter valued at about $376,000. Victory Capital Management Inc. grew its position in Nurix Therapeutics by 179.5% during the fourth quarter. Victory Capital Management Inc. now owns 60,212 shares of the company’s stock valued at $1,134,000 after acquiring an additional 38,672 shares during the period. Charles Schwab Investment Management Inc. grew its position in Nurix Therapeutics by 11.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 572,834 shares of the company’s stock valued at $10,792,000 after acquiring an additional 61,114 shares during the period. Finally, US Bancorp DE grew its position in Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after acquiring an additional 842 shares during the period.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,811 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the sale, the chief financial officer now owns 39,549 shares in the company, valued at $785,047.65. This represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,326 shares of company stock worth $213,449 over the last quarter. 7.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

NRIX has been the subject of a number of research reports. JPMorgan Chase & Co. lowered their price target on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Stephens reissued an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Morgan Stanley boosted their price target on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research report on Monday, February 3rd. Royal Bank of Canada boosted their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Finally, Needham & Company LLC decreased their target price on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.81.

Nurix Therapeutics Stock Performance

Shares of NRIX opened at $13.86 on Friday. The company has a market capitalization of $1.05 billion, a P/E ratio of -4.80 and a beta of 2.18. Nurix Therapeutics, Inc. has a one year low of $11.90 and a one year high of $29.56. The stock has a 50-day moving average price of $18.07 and a 200 day moving average price of $21.55.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.